Completed PHASE2 INTERVENTIONAL NCT00028288

Study of Daclizumab in Patients With Chronic, Persistent Asthma

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Daclizumab in Patients With Chronic, Persistent Asthma

Sponsor: Facet Biotech

Conditions Asthma

Interventions Daclizumab

Updated 6 times since 2017 Last updated: Mar 9, 2012 Started: Sep 30, 2001 Primary completion: Dec 31, 2003 Completion: Dec 31, 2003

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Asthma, this trial is completed. The trial is conducted by Facet Biotech and has accumulated 6 data snapshots since 2001. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Sep 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Facet Biotech

Data source: Facet Biotech

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bloomington, United States , Dallas, United States , Denver, United States , Easton, United States , Lake Oswego, United States , Long Beach, United States , Madison, United States , Miami, United States , Milwaukee, United States , Minneapolis, United States and 7 more locations